United Therapeutics' PAH Drugs Top $2.18B Sales in First 9M 2025
United Therapeutics’ PAH portfolio generated $2.18 billion in sales during the first nine months of 2025, led by $1.41 billion from Tyvaso, $398.8 million from Remodulin and $375.7 million from Orenitram. These figures highlight UTHR’s competitive positioning ahead of Merck’s new PAH entrant, Winrevair.
1. Strong PAH Franchise Performance
United Therapeutics reported combined first nine-month 2025 sales of $2.18 billion across its PAH drugs, with Tyvaso leading at $1.41 billion, Remodulin at $398.8 million and Orenitram at $375.7 million. This growth underscores the franchise’s resilience amid evolving market dynamics.
2. Competitive Landscape with Merck
Merck’s newly launched PAH drug, Winrevair, achieved $1.4 billion in full-year 2025 sales, positioning it as a direct competitor to UTHR’s established therapies. Market share implications will depend on Winrevair’s continued uptake in early-stage indications.
3. Pipeline and Future Outlook
Beyond the core PAH portfolio, United Therapeutics is advancing next-generation formulations and exploring new indications to sustain growth. Upcoming clinical readouts and potential label expansions will be critical for maintaining its market leadership.
4. Strategic Implications
Maintaining robust pricing and managing potential generic or biosimilar entries remain key priorities. UTHR’s investment in manufacturing capacity and patient support programs is designed to bolster market penetration and defend its PAH franchise.